<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DERMA-SMOOTHE/FS- fluocinolone acetonide oil </strong><br>Royal Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Derma-Smoothe/FS<span class="Sup">®</span> safely and effectively. See full prescribing information for Derma-Smoothe/FS<span class="Sup">®</span>.<br>Derma-Smoothe/FS<span class="Sup">®</span> (fluocinolone acetonide) Topical Oil, 0.01%<br>(Body Oil)<br>For Topical Use Only<br>Not for Oral, Ophthalmic, or Intravaginal Use<br>NDC 68791-101-04<br>Initial U.S. Approval: 1988 </div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indication and Usage, Pediatric Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span> (<a href="#S1.2">1.2</a>) 11/2007 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Derma-Smoothe/FS<span class="Sup">®</span> is a corticosteroid indicated for the </p>
<ul>
<li>topical treatment of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in adult patients (<a href="#S1.1">1.1</a>)</li>
<li>topical treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in pediatric patients 3 months and older for up to 4 weeks (<a href="#S1.2">1.2</a>)</li>
</ul>
<p class="Highlighta">Limitations of Use: </p>
<ul>
<li>Apply the least amount to cover affected areas.<br>Discontinue when disease is controlled. (<a href="#S1.3">1.3</a>) </li>
<li>Do not use in the diaper area. (<a href="#S1.3">1.3</a>)</li>
<li>Do not use on the face, axillae, or groin. (<a href="#S1.3">1.3</a>, <a href="#S6.2">6.2</a>, <a href="#S8.4">8.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Derma-Smoothe/FS<span class="Sup">®</span> is not for oral, ophthalmic, or intravaginal use.(<a href="#S2">2</a>) </p>
<ul>
<li>Adult patients: Apply to affected areas 3 times daily. (<a href="#S2.1">2.1</a>)</li>
<li>Pediatric patients: Moisten skin and apply to affected areas twice daily for up to 4 weeks. (<a href="#S2.2">2.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Derma-Smoothe/FS<span class="Sup">®</span> (fluocinolone acetonide) Topical Oil, 0.01% (Body Oil) is supplied in bottles containing 4 fluid ounces. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Topical corticosteroids can produce reversible HPA axis suppression, Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria. (<a href="#S5.1">5.1</a>)</li>
<li>Systemic absorption may require evaluation for hypothalamic-pituitary-adrenal (HPA) axis suppression. (<a href="#S5.1">5.1</a>)</li>
<li>Modify use should HPA axis suppression develop. (<a href="#S5.1">5.1</a>)</li>
<li>Potent corticosteroids use on large areas, prolonged use or occlusive use may increase systemic absorption. (<a href="#S5.1">5.1</a>)</li>
<li>Local adverse reactions may include <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, irritation, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> and may be more likely with occlusive use or more potent corticosteroids (<a href="#S5.2">5.2</a>,<a href="#S5.3">5.3</a>,<a href="#S6.1">6.1</a>)</li>
<li>Children may be more susceptible to systemic toxicity from equivalent doses. (<a href="#S5.1">5.1</a>,<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥ 5%) were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (20%), <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (13%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (10% ), <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span> (7%), <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (7%), and hypopigmentation (7%).  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Hill Dermaceuticals, Inc. at 1-800-344-5707 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Adult Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Pediatric Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hypothalamic-Pituitary-Adrenal Axis Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Local Adverse Reactions with Topical Corticosteroids</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic Contact Dermatitis</span> with Topical Corticosteroids</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin Infections</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use in Peanut-Sensitive Individuals</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience: Evaluation of Facial Use in Pediatric Subjects</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Studies Experience: Evaluation in Pediatric Subjects 3 months to 2 years old</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-8" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, mutagenesis, impairment of fertility</a></h2>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED / STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Adult Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></h2>
<p class="First">Derma-Smoothe/FS<span class="Sup">®</span> is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Pediatric Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></h2>
<p class="First">Derma-Smoothe/FS<span class="Sup">®</span> is indicated for the topical treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in pediatric patients, 3 months and older for up to 4 weeks. Safety and effectiveness in pediatric patients younger than 3 months of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">Apply the least amount of Derma-Smoothe/FS<span class="Sup">®</span> needed to cover the affected areas. As with other corticosteroids, Derma-Smoothe/FS<span class="Sup">®</span> should be discontinued when control of disease is achieved. Contact the physician if no improvement is seen within 2 weeks.</p>
<p>Derma-Smoothe/FS<span class="Sup">®</span> should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use.</p>
<p>Derma-Smoothe/FS<span class="Sup">®</span> should not be used on the face, axillae, or groin unless directed by the physician. Application to intertriginous areas should be avoided due to the increased risk of local adverse reactions. <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a> and <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Derma-Smoothe/FS<span class="Sup">®</span> is not for oral, ophthalmic, or intravaginal use.</p>
<p><span class="Bold">The dosing of Derma-Smoothe/FS<span class="Sup">®</span> is different for adult and pediatric patients.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></h2>
<p class="First">Apply Derma-Smoothe/FS<span class="Sup">®</span> as a thin film to the affected areas <span class="Underline">three times daily</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></h2>
<p class="First">Moisten skin and apply Derma-Smoothe/FS<span class="Sup">®</span> as a thin film to the affected areas <span class="Underline">twice daily for up to four weeks</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Derma-Smoothe/FS<span class="Sup">®</span> (fluocinolone acetonide), Topical Oil, 0.01% (Body Oil) is supplied in bottles containing 4 fluid ounces.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hypothalamic-Pituitary-Adrenal Axis Suppression</h2>
<p class="First">Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria can also be produced by systemic absorption of topical corticosteroids.</p>
<p>Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.</p>
<p>If HPA axis suppression is documented, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids.</p>
<p>Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, and use of occlusive dressings. Manifestations of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> may require supplemental systemic corticosteroids.</p>
<p>Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> ratios. <span class="Italics">[See <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Local Adverse Reactions with Topical Corticosteroids</h2>
<p class="First">Local adverse reactions may occur with use of topical corticosteroids and may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasias</span>, burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>. <span class="Italics">[See <a href="#S6.1">Adverse Reactions (6.1)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic Contact Dermatitis</span> with Topical Corticosteroids</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> to any component of topical corticosteroids is usually diagnosed by a <span class="Italics">failure to heal</span> rather than a clinical exacerbation. Clinical diagnosis of <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> can be confirmed by patch testing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin Infections</span></h2>
<p class="First">Concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> should be treated with an appropriate antimicrobial agent. If the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> persists unchanged, Derma-Smoothe/FS<span class="Sup">®</span> should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately treated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use in Peanut-Sensitive Individuals</h2>
<p class="First">Physicians should use caution in prescribing Derma-Smoothe/FS<span class="Sup">®</span> for peanut-sensitive individuals. <span class="Italics">[See <a href="#S11">Description (11)</a>]</span></p>
<p>Should signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> present (wheal and flare reactions, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, or other manifestations), or should disease exacerbations occur, Derma-Smoothe/FS<span class="Sup">®</span> should be discontinued immediately and appropriate therapy instituted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience: Evaluation of Facial Use in Pediatric Subjects</h2>
<p class="First">An open-label study was conducted in 58 children with moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> (2 to 12 years old) to evaluate the safety of Derma-Smoothe/FS<span class="Sup">®</span> when applied to the face twice daily for 4 weeks. The following adverse reactions were reported:</p>
<table width="100%">
<caption><span>Incidence of Adverse Reactions (%), N=58</span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead><tr class="First Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Adverse Reaction (AR)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></td>
<td class="Rrule" align="center"><span class="Bold"># of subjects (%)</span></td>
<td class="Rrule" align="center"><span class="Bold">Day 14</span></td>
<td class="Rrule" align="center"><span class="Bold">Day 28<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></span></td>
<td class="Rrule" align="center"><span class="Bold">Day 56<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></span></td>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The number of individual adverse reactions reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reporting of an adverse reaction.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>End of Treatment</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Four Weeks Post Treatment</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any AE</td>
<td class="Rrule" align="center">15 (26)</td>
<td class="Rrule" align="center">6 (10)</td>
<td class="Rrule" align="center">7 (12)</td>
<td class="Rrule" align="center">7 (12)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">Telangiectasia</span></td>
<td class="Rrule" align="center">5 (9)</td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center">4 (7)</td>
<td class="Rrule" align="center">2 (4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">3 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">3 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Irritation</td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">3 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Burning</td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">3 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hypopigmentation</td>
<td class="Rrule" align="center">2 (4)</td>
<td class="Rrule" align="center">2 (4)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Shiny skin</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Secondary <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">Papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197127" conceptname="Keratosis pilaris">Keratosis pilaris</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Facial herpes simplex</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">Acneiform eruption</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear infection</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Studies Experience: Evaluation in Pediatric Subjects 3 months to 2 years old</h2>
<p class="First">An open-label safety study was conducted in 29 children to assess the HPA axis by ACTH stimulation testing following use of Derma-Smoothe/FS<span class="Sup">®</span> twice daily for 4 weeks. The following adverse reactions were reported in the study [See <span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4)</a></span>];</p>
<table width="80%">
<caption><span>Adverse Reactions (%), N=30<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<thead><tr class="First Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Adverse Reaction</span></td>
<td class="Rrule" align="center"><span class="Bold"># of subjects (%)</span></td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Includes one subject who withdrew at Week 2</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">3 (10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Molluscum</td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">2 (7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">URI</td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">6 (20)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
<td class="Rrule" align="center">4 (13)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hyperpigmentation</td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hypopigmentation</td>
<td class="Rrule" align="center">2 (7)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">1 (3)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.1.1"></a><p></p>
<p class="First">Pregnancy Category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</p>
<p>There are no adequate and well-controlled studies in pregnant women on teratogenic effects from Derma-Smoothe/FS<span class="Sup">®</span>. Therefore, Derma-Smoothe/FS<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.</p>
<p>Because many drugs are excreted in human milk, caution should be exercised when Derma-Smoothe/FS<span class="Sup">®</span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<p class="First"><span class="Bold">8.4.1 Systemic Adverse Reactions in Pediatric Patients</span></p>
<p>HPA axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, low plasma cortisol levels, and subnormal response to ACTH stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
<p>Because of a higher ratio of skin surface area to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, children are at a greater risk for systemic adverse reactions than are adults when treated with topical corticosteroids. <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<p class="First"><span class="Bold">8.4.2 Evaluation in Peanut-Sensitive Pediatric Subjects</span></p>
<p>A clinical study was conducted to assess the safety of Derma-Smoothe/FS<span class="Sup">®</span>, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 subjects with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, 6 to 17 years of age. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the subjects' responses to both prick test and patch test utilizing peanut oil NF, Derma-Smoothe/FS<span class="Sup">®</span> and histamine/saline controls. Subjects were also treated with Derma-Smoothe/FS<span class="Sup">®</span> twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to Derma-Smoothe/FS<span class="Sup">®</span> and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> after 5 days of Derma-Smoothe/FS<span class="Sup">®</span>. The bulk peanut oil NF, used in Derma-Smoothe/FS<span class="Sup">®</span> is heated at 475°F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins. <span class="Italics">[See <a href="#S11">Description (11)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<p class="First"><span class="Bold">8.4.3 Evaluation in Pediatric Subjects 2 to 6 years old</span></p>
<p>Open-label safety studies were conducted on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>. Subjects were treated with Derma-Smoothe/FS<span class="Sup">®</span> twice daily for 4 weeks. Baseline body surface area involvement was 50% to 75% in 15 subjects and greater than 75% in 18 subjects. Morning pre-stimulation cortisol and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 µg/dL; normal: cortisol &gt; 7µg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 µg/dL).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.4"></a><p></p>
<p class="First"><span class="Bold">8.4.4 Evaluation in Pediatric Subjects 3 months to 2 years old</span></p>
<p>An open-label safety study was conducted in 29 children (7 subjects ages 3 to 6 months, 7 subjects ages &gt; 6 to 12 months and 15 subjects ages &gt; 12 months to 2 years of age) to assess the HPA axis by ACTH stimulation testing following use of Derma-Smoothe/FS<span class="Sup">®</span> twice daily for 4 weeks. All subjects had moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> with disease involvement on at least 20% body surface area. Baseline body surface area involvement was 50% to 75% in 11 subjects and greater than 75% in 7 subjects. Morning pre-stimulation and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. All subjects had normal responses to 0.125 mg of ACTH stimulation (cortisol &gt; 18 µg/dL).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-8"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects, including under conditions of normal use. <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Derma-Smoothe/FS<span class="Sup">®</span> (fluocinolone acetonide), Topical Oil, 0.01% (Body Oil) contains fluocinolone acetonide [(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17 [(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use.</p>
<p>This formulation is also marketed as Derma-Smoothe/FS<span class="Sup">®</span> (fluocinolone acetonide), Topical Oil, 0.01% (Scalp Oil) for use with shower caps for treatment of scalp <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> in adults, and as fluocinolone acetonide oil, 0.01% for treatment of chronic eczematous external <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>. Chemically, fluocinolone acetonide is C<span class="Sub">24</span> H<span class="Sub">30</span> F<span class="Sub">2</span> O<span class="Sub">6</span>. It has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc61c619-a71c-46f5-80f1-9e9ee71134aa&amp;name=7d77937f-c3a3-49ec-85f0-cbd991c31e66-01.jpg"></div>
<p>Fluocinolone acetonide in Derma-Smoothe/FS<span class="Sup">®</span> has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.</p>
<p>Each gram of Derma-Smoothe/FS<span class="Sup">®</span> contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil NF and fragrances.</p>
<p>Derma-Smoothe/FS<span class="Sup">®</span> is formulated with 48% refined peanut oil NF. The peanut oil used in Derma-Smoothe/FS<span class="Sup">®</span> is tested for peanut proteins through amino acid analysis which can detect the quantity of amino acids to below 0.5 parts per million.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and/or other disease processes in the skin may increase percutaneous absorption. </p>
<p>The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.</p>
<p>Derma-Smoothe/FS<span class="Sup">®</span> is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Derma-Smoothe/FS<span class="Sup">®</span>. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in Derma-Smoothe/FS<span class="Sup">®</span>. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. the <span class="Italics">in vitro</span> human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the in vivo mouse bone marrow micro nucleus assay, the Chinese hamster micronucleus test, and the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> gene mutation assay).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED / STORAGE AND HANDLING</h1>
<p class="First">Derma-Smoothe/FS<span class="Sup">®</span> is supplied in bottles containing 4 fluid ounces. It is labeled as Body Oil (<span class="Bold">NDC # 68791-101-04</span>).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Storage: Store at 25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Instructions</h2>
<ul>
<li>Derma-Smoothe/FS<span class="Sup">®</span> should be used as directed by the physician. It is for external use only. Avoid contact with the eyes. In case of contact, wash eyes liberally with water.</li>
<li>Derma-Smoothe/FS<span class="Sup">®</span> should not be used for any disorder other than that for which it was prescribed.</li>
<li>Patients should report any worsening of their skin condition to their physician promptly.</li>
<li>Derma-Smoothe/FS<span class="Sup">®</span> should not be applied under occlusion unless directed by the physician. Derma-Smoothe/FS<span class="Sup">®</span> should not be applied to the diaper area as diapers or plastic pants may constitute occlusive use.</li>
<li>Derma-Smoothe/FS<span class="Sup">®</span> should not be used on the face, axillae, or groin unless directed by the physician.</li>
<li>As with other corticosteroids, therapy should be discontinued when control of disease is achieved. Contact the physician if no improvement is seen within 2 weeks.</li>
<li>Do not use other corticosteroid-containing products while using Derma-Smoothe/FS<span class="Sup">®</span> without first consulting your physician.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured by:<br>Hill Dermaceuticals, Inc.<span class="Sup">®</span><br>Sanford, FL 32773<br>1.800.344.5707</p>
<p>For: Royal Pharmaceuticals, Inc<br>Manasquan, NJ 08736<br>1.800.510.3401</p>
<p>Rev. CODE 171A240-0 <br>Date: 6/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 118.28 mL Bottle Label</span></p>
<p><span class="Bold">NDC 68791-101-04</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Derma-Smoothe/FS<span class="Sup">®</span></span></p>
<p><span class="Bold">Fluocinolone Acetonide<br>0.01% Topical Oil</span></p>
<p><span class="Bold">(BODY OIL)</span></p>
<p><span class="Bold">FOR TOPICAL USE ONLY<br>NOT FOR ORAL, OPHTHALMIC,<br>or INTRAVAGINAL USE</span></p>
<p><span class="Bold">SHAKE WELL BEFORE USE</span></p>
<p><span class="Bold">Net Contents 118.28 mL<br>(4 fL. oz.)</span></p>
<p><span class="Bold">ROYAL<br>PHARMACEUTICALS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 118.28 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc61c619-a71c-46f5-80f1-9e9ee71134aa&amp;name=7d77937f-c3a3-49ec-85f0-cbd991c31e66-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DERMA-SMOOTHE/FS 		
					</strong><br><span class="contentTableReg">fluocinolone acetonide oil</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68791-101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fluocinolone acetonide</strong> (fluocinolone acetonide) </td>
<td class="formItem">fluocinolone acetonide</td>
<td class="formItem">0.11 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL MYRISTATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LIGHT MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>OLETH-2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEANUT OIL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68791-101-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">118.28 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019452</td>
<td class="formItem">02/16/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Royal Pharmaceuticals
							(078374385)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7d77937f-c3a3-49ec-85f0-cbd991c31e66</div>
<div>Set id: bc61c619-a71c-46f5-80f1-9e9ee71134aa</div>
<div>Version: 2</div>
<div>Effective Time: 20130820</div>
</div>
</div> <div class="DistributorName">Royal Pharmaceuticals</div></p>
</body></html>
